Literature DB >> 30232400

Increased expression of miR-33a in monocytes from Mexican hypertensive patients in elevated carotid intima-media thickness.

Yazmín Estela Torres-Paz1, Claudia Huesca-Gómez1, Fausto Sánchez-Muñoz2, Rocío Martínez-Alvarado3, Ma Elena Soto2, Margarita Torres-Tamayo3, Giovanny Fuentevilla-Álvarez1, Ricardo Gamboa4.   

Abstract

miR-33a has been described as a key regulator in the initiation and progression of atherosclerosis. However, its role in arterial hypertension (HTA) has not been elucidated. Therefore, the aim of this study was to determine the association between the expression of miR-33a (5p and 3p) and the carotid intima-media thickness (cIMT) in samples of monocytes and serum from hypertensive patients. The miR-33a-5p and miR-33a-3p expression in monocytes and serum from Mexican hypertensive patients were examined by RT-PCR. This study involved 84 subjects (42 normotensive subjects and 42 patients with essential hypertension). Our study revealed that miR-33a-5p expression was significantly upregulated in the monocytes of hypertensive patients compared with the control group (p = 0.001), while miR-33a-3p was significantly downregulated (p = 0.013). miR-33a-5p upregulation [OR: 5.53, 95% CI: 2.01-15.20; p = 0.001], as well as miR-33a-3p downregulation [OR: 3.32, 95% CI: 1.45-7.60; p = 0.004] in monocytes, was associated with an increased risk of developing hypertension. In addition, miR-33a-5p upregulation in hypertensive patients was associated with an increased risk of presenting cIMT [OR: 5.99, 95% CI: 1.10-32.85; p = 0.039]. Moreover, we found no significant differences in the expression of both strands of miR-33a in serum of our patients. Our results showed an upregulation of miR-33a-5p and downregulation of miR-33a-3p in monocytes, these data are associated with cIMT, which could be a risk factor for the development of hypertension. In addition, upregulation of miR-33a-5p in monocytes from Mexican hypertensive patients could be involved in the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30232400     DOI: 10.1038/s41371-018-0102-x

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  33 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  MicroRNAs regulating lipid metabolism in atherogenesis.

Authors:  K J Rayner; C Fernandez-Hernando; K J Moore
Journal:  Thromb Haemost       Date:  2012-01-25       Impact factor: 5.249

Review 3.  MicroRNA-33 in atherosclerosis etiology and pathophysiology.

Authors:  Wu-Jun Chen; Min Zhang; Guo-Jun Zhao; Yuchang Fu; Da-Wei Zhang; Hai-Bo Zhu; Chao-Ke Tang
Journal:  Atherosclerosis       Date:  2012-12-04       Impact factor: 5.162

Review 4.  Epigenetic Biomarkers and Cardiovascular Disease: Circulating MicroRNAs.

Authors:  David de Gonzalo-Calvo; Eduardo Iglesias-Gutiérrez; Vicenta Llorente-Cortés
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2017-06-13

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

7.  [What measure of carotid wall thickening is the best atherosclerotic loading score in the hypertensive patient: maximum or mean value?].

Authors:  Irene Mateo; Pedro Morillas; Juan Quiles; Jesús Castillo; Helder Andrade; Julián Roldán; Pilar Agudo; Vicente Bertomeu-Martínez
Journal:  Rev Esp Cardiol       Date:  2011-03-15       Impact factor: 4.753

Review 8.  Functions of microRNA-33a/b and microRNA therapeutics.

Authors:  Koh Ono
Journal:  J Cardiol       Date:  2015-11-29       Impact factor: 3.159

9.  Frequent co-expression of miRNA-5p and -3p species and cross-targeting in induced pluripotent stem cells.

Authors:  Chiu-Jung Huang; Phan Nguyen Nhi Nguyen; Kong Bung Choo; Shigeki Sugii; Kenneth Wee; Soon Keng Cheong; Tunku Kamarul
Journal:  Int J Med Sci       Date:  2014-06-05       Impact factor: 3.738

10.  Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease.

Authors:  Jing Dong; Ying-Zhi Liang; Jie Zhang; Li-Juan Wu; Shuo Wang; Qi Hua; Yu-Xiang Yan
Journal:  J Atheroscler Thromb       Date:  2016-09-13       Impact factor: 4.928

View more
  3 in total

1.  Comment on the potential role of microRNAs in hypertension.

Authors:  Durairaj Sekar
Journal:  J Hum Hypertens       Date:  2018-09-19       Impact factor: 3.012

2.  Perillyl alcohol and quercetin modulate the expression of non-coding RNAs MIAT, H19, miR-29a, and miR-33a in pulmonary artery hypertension in rats.

Authors:  Soodeh Rajabi; Hamid Najafipour; Mozhgan Sheikholeslami; Saeideh Jafarinejad-Farsangi; Ahmad Beik; Majid Askaripour; Zahra Miri Karam
Journal:  Noncoding RNA Res       Date:  2022-01-28

3.  Blood microRNA 202-3p associates with the risk of essential hypertension by targeting soluble ST2.

Authors:  Lu Li; Danrong Zhong; Yudan Xie; Xinlei Yang; Zuozhong Yu; Dangui Zhang; Xinghua Jiang; Yanqing Wu; Fangqin Wu
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.